LM22A-4

LM22A-4 is a synthetic, selective small-molecule partial agonist of TrkB (EC₅₀ for TrkB activation = 200–500 pM; IC₅₀ for inhibition of BDNF binding to TrkB = 47 nM; IA = ~85%), the main receptor of brain-derived neurotrophic factor.^[1][2][3] It has been found to possess poor blood-brain-barrier penetration when administered systemically, so LM22A-4 has been given to animals instead via intranasal administration, with central nervous system TrkB activation observed.^[3][4] The compound produces neurogenic and neuroprotective effects in animals,^[3][5][6] and shows beneficial effects on respiration in animal models of Rett syndrome.^{[2][citation needed][7]}

LM22A-4

Clinical data
ATC code	None
Identifiers
IUPAC name 1-N,3-N,5-N-tris(2-Hydroxyethyl)benzene-1,3,5-tricarboxamide
CAS Number	37988-18-4 Y
PubChem CID	2054170
ChemSpider	1548402
UNII	5GCL3P6AF5
CompTox Dashboard (EPA)	DTXSID201045819
Chemical and physical data
Formula	C15H21N3O6
Molar mass	339.348 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=C(C=C(C=C1C(=O)NCCO)C(=O)NCCO)C(=O)NCCO
InChI InChI=1S/C15H21N3O6/c19-4-1-16-13(22)10-7-11(14(23)17-2-5-20)9-12(8-10)15(24)18-3-6-21/h7-9,19-21H,1-6H2,(H,16,22)(H,17,23)(H,18,24) Key:RGWJKANXFYJKHN-UHFFFAOYSA-N

See also

• Tropomyosin receptor kinase B § Agonists